Peptide library › Cancer & imaging
Degarelix
Also known as Firmagon
Monthly hormone-blocking injection for advanced prostate cancer that lowers testosterone fast, without an initial flare.
What people use it for
- Advanced prostate cancer
What Degarelix does in the body
A GnRH antagonist: it blocks the brain's hormone signal directly, so testosterone falls within days. Unlike GnRH agonists, there's no temporary rise first.
Strength of evidence
Strong: Phase 3 trials showed testosterone suppression at least as good as leuprolide.
Look up the evidence
- Reviews on PubMed: Summaries of the published research
- Clinical trials on PubMed: Published studies in people
- ClinicalTrials.gov: Registered trials, past and ongoing
- Prescribing information (DailyMed, US): Official US label
- Patient leaflets (emc, UK): Official UK product information
Live searches of official databases. New to the terms? See the glossary.
Reported side effects & risks
- Injection-site pain and lumps
- Hot flushes
- Weight gain and tiredness
- Bone thinning with long-term use
- Heart rhythm changes (QT prolongation)
Who should avoid it or take extra care
- Heart rhythm problems (long QT) need caution
Not a complete list. Check with a doctor or pharmacist about your own health and medicines.
Regulatory status
FDA-approved in 2008. Prescription only.
How it's taken
Route: Injection under the skin of the abdomen: a starting dose, then every 28 days
How long it lasts (half-life): About 7 weeks for the monthly depot
Storage
Stored and prepared by the pharmacy or clinic, following the product label.
Latest research & news
- Development and Validation of a Stability-Indicating HPLC Method for Degarelix and Characterization of Its Degradation Impurities Using LC-MS, (1)H NMR, and FTIR Techniques
Research · Study · PubMed · Biomed Chromatogr · 21 Nov 2026 - Short-acting induction, long-acting maintenance: real-world trajectories of GnRH antagonist and agonist therapy for prostate cancer in Japan
Research · Study · PubMed · Int Urol Nephrol · 19 Nov 2026 - Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Clinical trial · Not yet recruiting · Early phase 1 · Updated · ClinicalTrials.gov · 18 Nov 2026 - Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Clinical trial · Not yet recruiting · Early phase 1 · Updated · ClinicalTrials.gov · 18 Nov 2026 - NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Clinical trial · Terminated · Phase 1 · Updated · ClinicalTrials.gov · 17 Nov 2026
Picked automatically from PubMed, ClinicalTrials.gov and the FDA, and updated daily. Early, lab and animal studies often don't carry over to people.
Keep track of Degarelix privately
Fiala is a free app for logging doses, tracking vials and setting reminders. No account, and everything you log stays on your phone.
Open Degarelix in Fiala How to installMore in Cancer & imaging
- Lutetium Lu-177 dotatateTargeted radiation therapy that delivers radiation straight to neuroendocrine tumours.
- Lutetium Lu-177 vipivotide tetraxetanTargeted radiation therapy for advanced prostate cancer that carries the PSMA protein.
- Gallium Ga-68 dotatateRadioactive tracer used in PET scans to find neuroendocrine tumours.
- MotixafortideInjection that releases stem cells from the bone marrow so they can be collected before a transplant for multiple myeloma.
- BalixafortideExperimental CXCR4 blocker studied with chemotherapy for advanced breast cancer; its Phase 3 trial failed.
- LTX-315Experimental cancer-killing peptide injected directly into tumours to trigger an immune response.